These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 8422003

  • 1. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.
    Zannad F.
    Am J Cardiol; 1993 Jan 21; 71(3):34A-39A. PubMed ID: 8422003
    [Abstract] [Full Text] [Related]

  • 2. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.
    Lee AF, MacFadyen RJ, Struthers AD.
    Eur J Heart Fail; 1999 Dec 21; 1(4):401-6. PubMed ID: 10937954
    [Abstract] [Full Text] [Related]

  • 3. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J, Fraccarollo D.
    Minerva Cardioangiol; 2003 Apr 21; 51(2):155-64. PubMed ID: 12783071
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct 15; 78(8):902-7. PubMed ID: 8888663
    [Abstract] [Full Text] [Related]

  • 5. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM, Plokker HW, Lok DJ, Boomsma F, van der Horst FA, van Veldhuisen DJ, van Gilst WH, Voors AA.
    Int J Cardiol; 2006 Jan 26; 106(3):367-72. PubMed ID: 16337046
    [Abstract] [Full Text] [Related]

  • 6. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
    van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW.
    Am J Cardiol; 1993 Jan 21; 71(3):21A-28A. PubMed ID: 8422000
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 21; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 8. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 21; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 9. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
    Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD.
    Am J Cardiol; 1995 Dec 15; 76(17):1259-65. PubMed ID: 7503007
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA, CHARM Investigators.
    Eur J Heart Fail; 2008 Feb 15; 10(2):157-63. PubMed ID: 18242128
    [Abstract] [Full Text] [Related]

  • 11. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG, Schencking M, Scheer C, Rupp H.
    Praxis (Bern 1994); 1997 Apr 02; 86(14):566-74. PubMed ID: 9198851
    [Abstract] [Full Text] [Related]

  • 12. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
    MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD.
    Heart; 1999 Jul 02; 82(1):57-61. PubMed ID: 10377310
    [Abstract] [Full Text] [Related]

  • 13. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA, Wendt C, Saborowski F.
    Fiziol Cheloveka; 2005 Jul 02; 31(6):97-105. PubMed ID: 16366159
    [Abstract] [Full Text] [Related]

  • 14. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
    Pitt D.
    Eur Heart J; 1995 Dec 02; 16 Suppl N():107-10. PubMed ID: 8682055
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Captopril and spironolactone therapy for refractory congestive heart failure.
    Dahlström U, Karlsson E.
    Am J Cardiol; 1993 Jan 21; 71(3):29A-33A. PubMed ID: 8422001
    [Abstract] [Full Text] [Related]

  • 17. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.
    Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, Bonizzato A, Graziani M, Anker SD, Coats AJ, Zardini P.
    J Am Coll Cardiol; 2001 Jun 01; 37(7):1808-12. PubMed ID: 11401115
    [Abstract] [Full Text] [Related]

  • 18. The clinical implications of aldosterone escape in congestive heart failure.
    Struthers AD.
    Eur J Heart Fail; 2004 Aug 01; 6(5):539-45. PubMed ID: 15301999
    [Abstract] [Full Text] [Related]

  • 19. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor.
    Kinugawa T, Ogino K, Kato M, Furuse Y, Shimoyama M, Mori M, Endo A, Kato T, Omodani H, Osaki S, Miyakoda H, Hisatome I, Shigemasa C.
    Gen Pharmacol; 1998 Jul 01; 31(1):93-9. PubMed ID: 9595286
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.